TCG Labs-Soleil
Lucinda Quan serves as the Chief Operating Officer and Co-Founder of TCG Labs-Soleil since November 2023. Prior to this role, Lucinda co-founded Aligos Therapeutics in April 2018, where responsibilities included serving as an Advisor and holding the position of EVP, Chief Business Officer, and General Counsel. Lucinda's previous experience includes serving as Executive Director for Transactions, Business Development & Licensing at Merck from January 2016 to April 2018 and as Vice President of Legal Affairs at Alios BioPharma until its acquisition by Johnson & Johnson in October 2014. Additionally, Lucinda held the role of Vice President, Legal Affairs and Associate General Counsel at InterMune until its acquisition by Roche in September 2014. Early career milestones include positions at Clifford Chance US LLP, Brobeck, Phleger & Harrison, and Luce, Forward, Hamilton & Scripps LLP. Lucinda holds a B.A. in Business Economics and a J.D. from the University of California, Los Angeles.
TCG Labs-Soleil
At TCG Labs-Soleil, we are establishing a pioneering venture-biotech model in collaboration with The Column Group. Our mission is to efficiently translate scientific insights into therapeutic solutions for patients facing serious diseases. Our approach integrates a dedicated venture fund (TCG Labs) with an evergreen R&D hub led by top-tier scientists (Soleil). This creates a powerful ecosystem forming and overseeing independent portfolio companies, each dedicated to single-asset biologic programs, guiding them from ideation to clinical proof of concept and positioning them for strategic partnerships and transformative medical advancements.